The invention of new drugs relies on the ability to test and validate the research. It hasn’t exactly been smooth sailing in recent years. In fact, it’s been notoriously difficult for organizations to conduct clinical trial recruitment successfully.
When Fasha Mahjoor launched Neoteryx, he planned to change the way dried capillary blood is collected, to become the most significant blood microsampling innovator in the modern marketplace. In that, he and his team have surely succeeded.
Topics: Clinical Diagnostics, Clinical Trials, Alternative to Dried Blood Spot, Animal Testing, Pediatrics, RNA / DNA from Dried Blood, Capillary Blood Sampling, Vet Diagnostics, Alternative to Venipuncture, Remote Patient Monitoring, Health and Wellness, Immunosuppressants
In an era of change, labs are responding with new and innovative approaches and considering new angles from science and business perspectives. One Austin-based lab, focused on personalized medicine, merits special attention.
The California Initiative for the Advancement of Precision Medicine (CIAPM) is a national public entity formulated to ignite rational precision medicine research on popular diseases. It recently funded a study that will apply microsampling techniques. The upcoming multi-method, longitudinal, prospective cohort study will engage 200 patients with stable ischemic heart disease (IHD).
Laboratories: It’s time to get off the reimbursement treadmill.
You’ll expand your test menu and open your options when you add remote biofluid collection to your toolkit.
At Neoteryx, we research, develop, and commercialize simple, economical, and convenient microsampling devices for the collection and transportation of blood and other biological fluids.
In its May 2018 recommendation, the Food and Drug Administration includes the use of dried blood spot sampling for biomedical validation. The future of clinical chemistry and pharmacology will emphasize the use of microsampling.